A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common
challenge for neurodegenerative diseases such as Alzheimer's disease (AD). Recent …

Background There is still a substantial unmet need for less invasive and lower-cost blood-
based biomarkers to detect brain Alzheimer's disease (AD) pathology. This study is aimed to …

Background There is an urgent need for cost-effective, easy-to-measure biomarkers to
identify subjects who will develop Alzheimer's disease (AD), especially at the pre …

Plasma phosphorylated tau species have been recently proposed as peripheral markers of
Alzheimer's disease (AD) pathology. In this cross-sectional study including 91 subjects …

Objective Detecting plasma tau biomarkers used to be impossible due to their low
concentrations in blood samples. Currently, new high-sensitivity assays made it a reality. We …

Abstract Introduction Diagnosis of Alzheimer's disease (AD) based on amyloid beta (A),
pathologic tau (T), and neurodegeneration (N) biomarkers in peripheral fluids promises to …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the
presence of extracellular amyloid plaques (senile plaques) and intracellular neurofibrillary …

The elevated level of cerebrospinal fluid (CSF) Tau and phosphorylated Tau181 (p-Tau181)
proteins are well established hallmarks of Alzheimer's disease (AD). Elevated level of p …

Background Novel phosphorylated-tau (p-tau) blood biomarkers (eg, p-tau181, p-tau217 or
p-tau231), are highly specific for Alzheimer's disease (AD), and can track amyloid-β (Aβ) and …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology …